Skip to main page content
Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Filters applied. Clear all
Case Reports
. 2012 May;5(2):212-5.
doi: 10.1159/000338617. Epub 2012 May 5.

Successful Treatment of Advanced Ovarian Cancer With Thermochemotherapy and Adjuvant Immune Therapy

Affiliations
Free PMC article
Case Reports

Successful Treatment of Advanced Ovarian Cancer With Thermochemotherapy and Adjuvant Immune Therapy

R Kleef et al. Case Rep Oncol. .
Free PMC article

Abstract

We report on a 4-year progression-free survival of a 54-year-old female first diagnosed in December 2007 with advanced bilateral ovarian cancer FIGO IIIc, disseminated peritoneal carcinosis and malignant diaphragm invasion. Treatment started in January 2008 with 6 cycles of Taxol 175 mg/m(2)/carboplatin AUC 5 in 3-week intervals. Twenty-four hours following each chemotherapy session, fever-range long-duration whole-body hyperthermia (WBH) was performed at the temperature plateau of 40°C body core temperature for 6 h. Three months after completion of chemotherapy, 4 more long-duration WBH procedures were performed in monthly intervals. Importantly, long-duration WBH was paralleled with intradermal vaccination of autologous dendritic cells. No other treatment was given to the patient. Four years following the first diagnosis, the patient is still in complete remission with no evidence of disease.

Keywords: Adjuvant immune therapy; Dendritic cell therapy; Ovarian cancer; Thermo-chemotherapy; Whole-body hyperthermia.

Figures

Fig. 1
Fig. 1
Development of tumor marker CA125. CHT = Chemotherapy; LD-WBH = long-duration WBH.

Similar articles

See all similar articles

References

    1. Ovary and primary peritoneal carcinoma . In: AJCC Cancer Staging Manual. 7th ed. Edge SB, Byrd DR, Compton CC, Fritz AG, Greene FL, Trotti A, editors. New York: Springer; 2010. pp. 493–506.
    1. Skitzki JJ, Repasky EA, Evans SS. Hyperthermia as an immunotherapy strategy for cancer. Curr Opin Investig Drugs. 2009;10:550–558. - PMC - PubMed
    1. Peer AJ, Grimm MJ, Zynda ER, Repasky EA. Diverse immune mechanisms may contribute to the survival benefit seen in cancer patients receiving hyperthermia. Immunol Res. 2010;46:137–154. - PubMed
    1. Kleef R. Journal Club Commentary. Forsch Komplementmed. 2011;18:97–101.
    1. Banchereau J, Steinmann RM. Dendritic cells and the control of immunity. Nature. 1998;392:245–252. - PubMed

Publication types

Feedback